Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 10:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 32 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Sponsor: Hanmi Pharmaceutical Company Limited Clear all
Completed Phase 3 Interventional Results available

Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise

NCT03353350
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
efpeglenatide (SAR439977), placebo
Drug
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
18 Years and older
Enrollment
406 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
32
States / cities
Birmingham, Alabama • Glendale, Arizona • Canoga Park, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2022 · Synced Sep 1, 2026, 10:07 PM EDT
Active, not recruiting Phase 2 Interventional

Study to Evaluate HM15275 in Obese or Overweight Subjects Without Diabetes Mellitus

NCT07205900
View directory record Official record
Conditions
Obese, Obesity
Interventions
HM15275, Placebo of HM15275
Drug
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
18 Years to 75 Years
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
14
States / cities
Chula Vista, California • Oak Lawn, Illinois • Ames, Iowa + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Sep 1, 2026, 10:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM15211(Efocipegtrutide)

NCT03374241
View directory record Official record
Conditions
Obesity
Interventions
HM15211 or Placebo
Biological
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Sep 1, 2026, 10:07 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea

NCT03770728
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Efpeglenatide SAR439977, Placebo, Background therapy: Metformin alone or in combination with SU
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
23
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2021 · Synced Sep 1, 2026, 10:07 PM EDT
Completed Phase 2 Interventional

Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes

NCT02057172
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
HM11260C, liraglutide, Placebo
Drug
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
18 Years to 74 Years
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
CA, California
Source: ClinicalTrials.gov public record
Updated Aug 8, 2016 · Synced Sep 1, 2026, 10:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of HM10760A (Long-acting Erythropoietin) in Healthy Adult Caucasian and Japanese Subjects

NCT01030315
View directory record Official record
Conditions
Healthy
Interventions
HM10760A or placebo
Drug
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
18 Years to 55 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
US, California
Source: ClinicalTrials.gov public record
Updated Feb 25, 2014 · Synced Sep 1, 2026, 10:07 PM EDT
Terminated Phase 2 Interventional

Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung

NCT02485652
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
HM61713
Drug
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
20 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
15
States / cities
Beverly Hills, California • Burbank, California • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2021 · Synced Sep 1, 2026, 10:07 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin

NCT03684642
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Efpeglenatide, Dulaglutide, Background therapy Metformin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
908 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
30
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 1, 2026, 10:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Phase 1 Study of PK and Safety of HM15912 (Sonefpeglutide) in Subjects With Normal and Severe Kidney Function

NCT05711381
View directory record Official record
Conditions
Renal Impairment
Interventions
HM15912
Drug
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
18 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
4
States / cities
Tustin, California • Miami, Florida • Miami Lakes, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Sep 1, 2026, 10:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study for Multiple Doses of HM15136(Efpegerglucagon) in Obese or Overweight Subjects With Comorbidities

NCT04167553
View directory record Official record
Conditions
Obese With Comorbidities, Overweight With Comorbidities, Type2 Diabetes
Interventions
HM15136, Placebo
Drug
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 26, 2025 · Synced Sep 1, 2026, 10:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Molar Potency Study of HM12460A in Healthy Subjects

NCT03330314
View directory record Official record
Conditions
Healthy Volunteers
Interventions
HM12460A
Biological
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
18 Years to 60 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced Sep 1, 2026, 10:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Assess HM15275 in Healthy and Obese Subjects.

NCT06481098
View directory record Official record
Conditions
Obesity
Interventions
HM15275, Placebo of HM15275
Drug
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Sep 1, 2026, 10:07 PM EDT
Recruiting Phase 1Phase 2 Interventional

A proof-of Concept Study to Assess Safety and Tolerability of HM15421/GC1134A in Patients With Fabry Disease

NCT06858397
View directory record Official record
Conditions
Fabry Disesase
Interventions
HM15421/GC1134A
Drug
Lead sponsor
GC Biopharma Corp
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
6
States / cities
Los Angeles, California • Kansas City, Kansas • Minneapolis, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Sep 1, 2026, 10:07 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Single and Multiple Ascending Dose Study of HM17321 in Healthy and Obese Participants

NCT07219589
View directory record Official record
Conditions
Obesity, Obese
Interventions
HM17321, Placebo of HM17321
Drug
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Sep 1, 2026, 10:07 PM EDT
Terminated Phase 3 Interventional Results available

Effect of Efpeglenatide on Cardiovascular Outcomes

NCT03496298
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Efpeglenatide (SAR439977), Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
4,076 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
79
States / cities
Sheffield, Alabama • Gilbert, Arizona • Surprise, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Sep 1, 2026, 10:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Molar Potency Study of HM12470 in Healthy Subjects

NCT03330327
View directory record Official record
Conditions
Healthy Subjects
Interventions
HM12470
Biological
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
18 Years to 60 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Nov 5, 2017 · Synced Sep 1, 2026, 10:07 PM EDT
Recruiting Phase 2 Interventional

Phase 2 Study to Assess the Safety, PK, and PD of Sonefpeglutide (HM15912) in SBS-IF Subjects

NCT04775706
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
HM15912 Active, Placebo
Drug
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 1, 2026, 10:07 PM EDT
Completed Phase 2 Interventional

Glycaemic Control of Monthly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes

NCT02081118
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
HM11260C, Placebo
Drug
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
18 Years to 74 Years
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 8, 2016 · Synced Sep 1, 2026, 10:07 PM EDT
Not listed Phase 1 Interventional

Multiple Ascending Dose Study of HM12470 in Type 1 and Type 2 Diabetes Mellitus

NCT03332849
View directory record Official record
Conditions
Type1 Diabetes Mellitus, Type2 Diabetes Mellitus
Interventions
HM12470
Biological
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Nov 5, 2017 · Synced Sep 1, 2026, 10:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM12460A

NCT01724814
View directory record Official record
Conditions
Healthy, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Interventions
HM12460A, Placebo
Drug
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
18 Years to 70 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Nov 7, 2017 · Synced Sep 1, 2026, 10:07 PM EDT
Not listed Phase 1 Interventional

A Phase 1b Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus

NCT02059564
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
HM11260C, Placebo, Victoza
Drug
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
18 Years to 70 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
California City, California
Source: ClinicalTrials.gov public record
Updated Feb 10, 2014 · Synced Sep 1, 2026, 10:07 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Alone or in Combination With Oral Antidiabetic Drug(s)

NCT03713684
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Efpeglenatide SAR439977, Placebo, Background therapy
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
22
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2021 · Synced Sep 1, 2026, 10:07 PM EDT
Recruiting Phase 1 Interventional

Dose Escalation and Expansion Study of HM16390 Alone or With Pembrolizumab in Advanced or Metastatic Solid Tumors

NCT06724016
View directory record Official record
Conditions
Advanced or Metastatic Solid Tumors
Interventions
HM16390, pembrolizumab
Drug
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
18 Years and older
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
2
States / cities
Boston, Massachusetts • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Sep 1, 2026, 10:07 PM EDT
Terminated Phase 1 Interventional

Multiple Ascending Dose Study of HM12460A in Type 2 Diabetes Mellitus

NCT03332836
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
HM12460A
Biological
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
18 Years to 70 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Mar 31, 2021 · Synced Sep 1, 2026, 10:07 PM EDT